GW will be a clinical trial site for Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate.
George Washington University to Participate in Sanofi Phase II COVID-19 Vaccine Trial
Latest News
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.